Previous 10 | Next 10 |
2023-10-12 13:26:41 ET More on Femasys, Jaguar Health, etc. Jaguar Health, Inc. (JAGX) Q2 2023 Earnings Call Transcript LogicMark, Inc. (LGMK) Q2 2023 Earnings Call Transcript Femasys regains Nasdaq compliance Jaguar Health's Napo Pharma gets patent in Japan ...
MARLBOROUGH, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that new precl...
2023-10-12 10:00:14 ET More on Health Care Select Sector SPDR BofA reports 10th consecutive week of equity inflows Citi turns cautious on pharmaceuticals and biotech Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR For further details see...
2023-10-12 08:22:14 ET More on Beyond Meat, SELLAS Life Sciences, etc. Beyond Meat Continues To Look Potentially Beyond Repair Beyond Meat: The Core Question Here Is Liquidity Beyond Meat: Pain Is Far From Over SELLAS gains on FDA orphan drug status for its S...
2023-10-11 12:45:29 ET Gainers: Matinas Biopharma Holdings ( MTNB ) +123% . Phio Pharmaceuticals Corp ( PHIO ) +58% . Athena Consumer Acquisition Corp ( ACAQ ) +55% . Tupperware Brands Corporation ( TUP ) +38% . Avalo Therapeutics ( AV...
2023-10-11 12:13:39 ET DENVER, Colo., Oct. 11, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Tempest Therapeutics (NASDAQ: TPST), Phio Pharma (NASDAQ: PHIO), Athena Consumer Acq (AMEX: ACAQ), Matinas Bi...
2023-10-11 11:51:06 ET DENVER, Colo., Oct 11, 2023 ( www.247marketnews.com )- Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has been running since announcing, this morning, the poster presentation of two key preclinical studies of its INTASYL compound PH-894 at the AACR-NCI-EORTC Internatio...
2023-10-11 10:00:00 ET More on Health Care Select Sector SPDR BofA reports 10th consecutive week of equity inflows Citi turns cautious on pharmaceuticals and biotech Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR For further details see...
--Preclinical data shows melanoma cells treated with PH-894 makes them more recognizable to immune cells, increasing potential for elimination --Preclinical data demonstrates the effectiveness of PH-894 as an antitumor cytotoxic agent (directly killing tumor cells) --Data to be pr...
MARLBOROUGH, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that its Presi...
News, Short Squeeze, Breakout and More Instantly...
Phio Pharmaceuticals Corp. Company Name:
PHIO Stock Symbol:
NASDAQ Market:
Phio Pharmaceuticals Corp. Website:
Marlborough, Massachusetts--(Newsfile Corp. - July 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells...
Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to ...
Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced i...